Research progress in ocular toxicities associated with dual target therapy of dabrafenib and trametinib
- VernacularTitle:达拉非尼联合曲美替尼双靶治疗相关眼毒性研究进展
- Author:
Shuohan HUANG
1
;
Mengmeng WANG
1
;
Xuan YE
1
;
Zihan GUO
1
;
Han SHAN
1
;
Qing ZHAI
1
;
Jiyong LIU
1
;
Qiong DU
1
Author Information
- Publication Type:Journal Article
- Keywords: Eye diseases; Eye injuries; Uveitis; Retinal diseases; Dabrafenib; Trametinib
- From: Adverse Drug Reactions Journal 2023;25(5):308-314
- CountryChina
- Language:Chinese
- Abstract: Dual target therapy of dabrafenib combined with trametinib (DabTram) plays an important role in the treatment of malignancies. Ocular toxicities are adverse reactions which are relatively uncommon but potentially serious in DabTram treatment. At present, there is a lack of systematic research on ocular toxicities caused by DabTram, leading to insufficient understanding of this problem. In this paper, the literature on DabTram-related ocular toxicities are systematically reviewed, especially focusing on the incidence, clinical characteristics, mechanisms of occurrence, therapeutic measures and so on, and the corresponding management pathways in clinical medication were proposed to provide references for safe use of DabTram in clinic.
